New options for COVID-19 vaccine delivery may be on the way. An intranasal vaccine developed at the University of Georgia is headed to clinical trials soon.
The UGA-based startup CyanVac has received funding from the federal government to begin clinical trials of an intranasal vaccine it developed, called CVXGA. The study will determine how the new vaccine stacks up against the FDA-approved mRNA vaccine.
CyanVac was founded by Professor Biao He of the College of Veterinary Medicine, who served on a White House panel that advised on the future of COVID vaccination. He was also named both UGA inventor and entrepreneur of the year.
CyanVac’s trial in the fall will focus on a subset of participants who are at a higher risk of developing severe cases of COVID-19.
